A Study of Clevidipine Butyrate Injectable Emulsion in the Treatment of Hypertensive Emergency and Sub-emergency
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 398 participants.
Also called NCT05783557
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 398 participants
- Registry
-
NCT05783557
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT05783557. Randomized; triple masking; primary purpose treatment. Start 2023-05-01 (anticipated); primary completion 2024-12-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Clevidipine Butyrate Injectable Emulsion in the Treatment of Hypertensive Emergency and Sub-emergency
- Condition
- Hypertensive Emergency
- Intervention (Drug)
- Clevidipine Butyrate Injectable Emulsion
- Intervention (Drug)
- Cleviprex®
- Lead sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Record details
- Record id
cardio:ct-nct05783557- Content hash
ec108508fe807643c0b607258466377757fdf9b4f6e3ff0ce0b679c536fbb198